December 6th, 2011

More enforcement and bigger fines may change illegal drug marketing, say Harvard researchers

By Susan Todd
The Star-Ledger

The nation’s pharmaceutical industry will have to be threatened with stiffer penalties and greater enforcement efforts before companies end their inappropriate marketing tactics, according to a study released yesterday by a group of researchers at Harvard Medical School.

Using Pfizer’s anti-seizure drug Neurontin as an example, the researchers tracked prescription-writing activity from the first public indication of a federal investigation through the time of the company’s ultimate settlement with authorities in 2004 over a practice known in the industry as off-label marketing.

Read more:


Add your own Comment